TORONTO, July 7 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) announced on June 26, 2008 that Frank Ricciuti had been appointed to the Company's Board of Directors. Associated with this appointment, Mr. Ricciuti will be granted 100,000 Theralase Technologies Inc. incentive stock options, exercisable for 5 years, vesting over 3 years at a strike price of $0.21.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications. The Theralase technology platform targets several diverse healthcare sectors: firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions, including arthritis; secondly, to bio-stimulate and accelerate wound care and healing, including bone fracture regeneration; and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancer, bacteria, viruses and fat cells.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of the contents of this

release.